Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 11/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | BRD4 | O60885 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638869 | 0.90 | PKM (0.62) | PKMTDP1MAPTBRD4ALDH1A1 | |
| SCHEMBL5167999 | 0.86 | PKM (0.65) | PKMTDP1MAPTBRD4ALDH1A1 | |
| SCHEMBL31681272 | 0.86 | PKM (0.65) | PKMTDP1MAPTBRD4ALDH1A1 | |
| SCHEMBL2585585 | 0.85 | PKM (1.00) | PKMTDP1MAPTALDH1A1LMNA | |
| SCHEMBL5841997 | 0.84 | PKM (0.80) | PKMTDP1MAPTALDH1A1LMNA | |
| SCHEMBL3038643 | 0.82 | TDP1 (0.65) | PKMTDP1MAPTALDH1A1GAA | |
| SCHEMBL14721092 | 0.81 | BRD4 (1.00) | BRD4 | |
| SCHEMBL2586153 | 0.81 | PKM (1.00) | PKMALDH1A1L3MBTL1 | |
| SCHEMBL153164 | 0.80 | PKM (0.60) | PKMTDP1MAPTBRD4 | |
| SCHEMBL688480 | 0.79 | PKM (0.79) | PKMTDP1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204002-B1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS | INTERNATIONAL SOC FOR DRUG DEVELOPMENT S R L (IT) | 2021-05-19 | — | — | EP | disclosed |
| EP-3204002-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS | International Society for Drug Development S.r.l. (IT) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055454-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2016-04-14 | — | — | WO | disclosed |
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1370527-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002070478-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | HYOU1, IDO1, OXER1 | PKM 4024/4885TDP1 298/4885MAPT 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.